Pub Date : 2021-01-01DOI: 10.18893/kakuigaku.arm.2137
{"title":"[The 55th Japan Nuclear Medicine Society Chugoku-Shikoku Regional Association].","authors":"","doi":"10.18893/kakuigaku.arm.2137","DOIUrl":"https://doi.org/10.18893/kakuigaku.arm.2137","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39491022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.18893/kakuigaku.58.S1
{"title":"[Joint Program].","authors":"","doi":"10.18893/kakuigaku.58.S1","DOIUrl":"https://doi.org/10.18893/kakuigaku.58.S1","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.18893/kakuigaku.arm.2136
{"title":"[The 95th Japan Nuclear Medicine Society Kanto Koshinetsu Regional Association].","authors":"","doi":"10.18893/kakuigaku.arm.2136","DOIUrl":"https://doi.org/10.18893/kakuigaku.arm.2136","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39398625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
131I-3-iodobenzylguanidine or 131I-iobenguane (3-(131I) iodobenzylguanidine or 131I-iobenguane [131I-MIBG]) is a radioactive agent that is specifically accumulated in tumor cells such as pheochromocytoma and neuroblastoma. Due to its cytotoxic beta ray emitted from 131I, it has been developed as an agent for radioisotope therapy and some researchers have reported its effectiveness. In this study, based on the patients' data from previous clinical trials of 131I-MIBG therapy, we evaluated the radiation safety for public exposure caused by radiation emitted from patients who received 131I-MIBG. In results, it was considered that public exposure and medical exposure of visitors and caregivers to the patients were less than their dose limit and dose constraint by complying the current criteria of the release of patients after therapy with 131I.
{"title":"[Radiation Protection Against Exposure from Patients Receiving <sup>131</sup>I-MIBG and Released from Radiation Treatment Room].","authors":"Anri Inaki, Hiroshi Wakabayashi, Daiki Kayano, Seigo Kinuya","doi":"10.18893/kakuigaku.tr.2106","DOIUrl":"https://doi.org/10.18893/kakuigaku.tr.2106","url":null,"abstract":"<p><p><sup>131</sup>I-3-iodobenzylguanidine or <sup>131</sup>I-iobenguane (3-(<sup>131</sup>I) iodobenzylguanidine or <sup>131</sup>I-iobenguane [<sup>131</sup>I-MIBG]) is a radioactive agent that is specifically accumulated in tumor cells such as pheochromocytoma and neuroblastoma. Due to its cytotoxic beta ray emitted from <sup>131</sup>I, it has been developed as an agent for radioisotope therapy and some researchers have reported its effectiveness. In this study, based on the patients' data from previous clinical trials of <sup>131</sup>I-MIBG therapy, we evaluated the radiation safety for public exposure caused by radiation emitted from patients who received <sup>131</sup>I-MIBG. In results, it was considered that public exposure and medical exposure of visitors and caregivers to the patients were less than their dose limit and dose constraint by complying the current criteria of the release of patients after therapy with <sup>131</sup>I.</p>","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39253998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Encouragement Award Summary 1].","authors":"","doi":"10.18893/kakuigaku.A3","DOIUrl":"https://doi.org/10.18893/kakuigaku.A3","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Encouragement Award Summary 2].","authors":"","doi":"10.18893/kakuigaku.A5","DOIUrl":"https://doi.org/10.18893/kakuigaku.A5","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.18893/kakuigaku.58.S9
{"title":"[Joint Program Abstracts].","authors":"","doi":"10.18893/kakuigaku.58.S9","DOIUrl":"https://doi.org/10.18893/kakuigaku.58.S9","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Encouragement Award Summary 3].","authors":"","doi":"10.18893/kakuigaku.A7","DOIUrl":"https://doi.org/10.18893/kakuigaku.A7","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Honorary membership card].","authors":"","doi":"10.18893/kakuigaku.A9","DOIUrl":"https://doi.org/10.18893/kakuigaku.A9","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Internal radiation therapy using 3-iodobenzylguanidine (131I) injection (131I-MIBG injection) will be applied in actual clinical practice soon. However, the NHI medical technical fee for the use of 131I-MIBG injection has not yet been set. The Japanese Society of Nuclear Medicine surveyed health resource use for internal radiation therapy using 131I via questionnaires sent to medical institutions that have used 131I-MIBG injection. Results showed that the necessary cost per patient is 1,912,671 JPY, which was based on the Draft Proposal for Medical Examination Value (Ver. 7.2) of the Japanese Health Insurance Federation for Surgery. 131I-MIBG injection is supposed to be administered once to each patient and the patient is followed up for 4 months after administration. The fee per treatment is calculated to be 478,168 JPY per month. The appropriate NHI medical technical fee is thus considered to be 47,817 points per month per patient per treatment, which can be claimed up to 4 times.
{"title":"[A Report on Health Resource Use in Internal Radiation Therapy with <sup>131</sup>I-MIBG].","authors":"Katsuhiko Kato, Soichi Nakamura, Yoshinori Matoba, Seigo Kinuya","doi":"10.18893/kakuigaku.tr.2103","DOIUrl":"https://doi.org/10.18893/kakuigaku.tr.2103","url":null,"abstract":"<p><p>Internal radiation therapy using 3-iodobenzylguanidine (<sup>131</sup>I) injection (<sup>131</sup>I-MIBG injection) will be applied in actual clinical practice soon. However, the NHI medical technical fee for the use of 131I-MIBG injection has not yet been set. The Japanese Society of Nuclear Medicine surveyed health resource use for internal radiation therapy using <sup>131</sup>I via questionnaires sent to medical institutions that have used <sup>131</sup>I-MIBG injection. Results showed that the necessary cost per patient is 1,912,671 JPY, which was based on the Draft Proposal for Medical Examination Value (Ver. 7.2) of the Japanese Health Insurance Federation for Surgery. <sup>131</sup>I-MIBG injection is supposed to be administered once to each patient and the patient is followed up for 4 months after administration. The fee per treatment is calculated to be 478,168 JPY per month. The appropriate NHI medical technical fee is thus considered to be 47,817 points per month per patient per treatment, which can be claimed up to 4 times.</p>","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39054540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号